-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
According to the latest data from the medical network on March 16th, the top 20 sales of sample hospitals in 2020 and the top 10 pharmaceutical company rankings released the
hospital market.
The top 20 drugs
are affected by the new crown epidemic according to the data information of the medical geographic drug comprehensive database (PDB) for the whole year of 2020.
In 2020, the market sales of sample hospitals in China's key cities were 221.
31 billion yuan, a drop of 13% compared with the sales in 2019
.
In the past year, due to the impact of the new crown epidemic, the number of outpatient visits in hospitals has dropped sharply.
Neurological, anti-infection, cardiovascular, digestive system, miscellaneous, immunosuppressive drugs, endocrine and metabolic regulation drugs, blood and hematopoietic system drugs, and anti-tumor drugs The sales of medicines in the therapeutic areas such as medicines all showed negative growth
.
In terms of breakdown, the drug categories with the largest decline are neurologic medications, anti-infective medications, and cardiovascular medications, all with a decline of more than 20%; the smallest decline is anti-tumor drugs, which is about 4%.
At the same time, With a market share of 30.
3 billion yuan, oncology drugs accounted for the largest market share compared to drugs used in other diseases
.
In China's overall sample market, there are only 83 drugs with sales of more than 500 million in 2020, and this figure is still 111 in 2019
.
Specifically, in 2020, the top 20 drugs in sample hospitals’ sales include: human albumin, sodium chloride injection, dezocine injection, pegylated recombinant human granulocyte stimulating factor injection, and beauty for injection Ropenem, bevacizumab injection, cefoperazone sodium and sulbactam sodium for injection, osimertinib mesylate tablets, trastuzumab for injection, iodixanol injection, intravenous human immunoglobulin (pH4 ), tacrolimus capsules, rituximab injection, recombinant human thrombopoietin injection, pemetrexed disodium for injection, piperacillin sodium and tazobactam sodium for injection, docetaxel injection Solution, paclitaxel for injection (albumin-bound type), oxaliplatin for injection, butylphthalide sodium chloride injection
.
8Large variety, sales increase.
Among the top 20 drugs, there are 8 drugs.
Compared with 2019, sales have achieved further growth.
They are: human albumin, pegylated recombinant human granulocyte stimulation Factor injection, bevacizumab injection, osimertinib mesylate tablets, iodixanol injection, tacrolimus capsules, recombinant human thrombopoietin injection, butylphthalide sodium chloride injection
.
Among them, the largest increase was osimertinib mesylate tablets.
Its sales in sample hospitals rose from 1 billion yuan in 2019 to 1.
54 billion yuan in 2020, an increase of 54.
2%
.
It can be said that this growth rate is exceptionally impressive compared to the 10% growth rate of other drugs that are showing positive growth
.
Osimertinib mesylate is AstraZeneca's third-generation lung cancer targeted drug, with global sales of US$3.
2 billion in 2019
.
The product was approved to enter the Chinese market in March 2017 and contributed more than 500 million yuan in revenue within 9 months
.
It is the first domestic tumor drug approved for locally advanced or metastatic non-small cell lung cancer with positive EGFR T790M mutation
.
In October 2018, osimertinib mesylate (Teresa) was included in medical insurance through special negotiations on anticancer drugs.
The negotiation determined that the medical insurance payment standard was 510 yuan per tablet (80mg), an apparent decrease of 27%
.
After entering the medical insurance catalogue, osimertinib quickly increased its volume.
In the fourth quarter of 2018, its sales exceeded 300 million yuan, and its annual sales in 2019 exceeded 2.
3 billion yuan
.
Subsequently, osimertinib successfully renewed its contract and entered the 2019 edition of the National Medical Insurance Negotiation Catalog.
The latest data shows that in 2020, osimertinib will further enjoy the mass effect of entering medical insurance in the hospital market
.
It is worth noting that in September 2019, osimertinib was approved for the second indication for local late or metastasis with epidermal growth factor receptor exon 19 deletion or exon 21 (L858R) substitution mutation First-line treatment for adult patients with sexual non-small cell lung cancer
.
With the approval of new indications, osimertinib will continue to release greater sales potential
.
12 varieties, fell
in the remaining sales fell 12 kinds of medicines, the largest decline in paclitaxel for injection (albumin-bound), a decline of up to 25%, ranking regress from 13 in 2019 to 2020 The 18th place
.
Paclitaxel for injection (albumin-binding type) is an anti-microtubule drug used to treat metastatic breast cancer that has failed combined chemotherapy or breast cancer that recurs within 6 months after adjuvant chemotherapy
.
According to data from Meinenet, in 2019, the terminal paclitaxel sales of public medical institutions in China exceeded 7.
5 billion yuan, and paclitaxel for injection (albumin-bound type) accounted for 38.
6% of the market share
.
Paclitaxel injection (albumin-bound) as the top-ranking sales of cancer drug because of production enterprises full three national organizations be included in the second batch of drugs Jicai, eventually the new base, stone medicine, Henry won the bid, which bid CSPC The lowest price-747 yuan / branch
.
In March 2019, Xinji’s paclitaxel for injection (albumin-binding type) was suspended by the State Food and Drug Administration because its production facilities did not meet the requirements of China’s GMP, and the Joint Procurement Office subsequently announced its cancellation of the eligibility for the selection.
The market selected by Xinji Central Procurement Partitioned by CSPC and Hengrui Pharmaceuticals
.
In the second round of national centralized procurement, the procurement cycle of paclitaxel for injection (albumin-bound type) was two years.
With the sharp price cuts in centralized procurement, the reduction in sales in the hospital market is also expected
.
There may also be pemetrexed disodium for injection, which is similar to paclitaxel albumin, which has also been included in the collection
.
Sample hospitals, the top 10 pharmaceutical companies
According to the latest data in 2020, the top 10 pharmaceutical companies in the sample hospitals’ sales are: AstraZeneca, Pfizer, Jiangsu Hengrui, Roche, Yangzijiang Pharmaceutical, Novartis, CSPC, Bayer, Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group
.
Among the top 10 pharmaceutical companies, only two have maintained positive growth.
They are CSPC and Qilu Pharmaceutical-Qilu Pharmaceutical's revenue in 2020 reached 4.
69 billion yuan, compared with 4.
27 billion yuan in 2019.
Increased revenue, an increase of 9.
8%
.
The top three pharmaceutical companies, AstraZeneca, Pfizer, and Jiangsu Hengrui, have revenues of 8.
86 billion yuan, 7.
72 billion yuan, and 6.
9 billion yuan, respectively, and their leading advantages are obvious
.
In general, among the top 10 pharmaceutical companies, domestic pharmaceutical companies and multinational pharmaceutical companies each occupy five seats, and the overall ranking of multinational pharmaceutical companies is high
.
From the perspective of total revenue, the total revenue of domestic pharmaceutical companies is 26.
34 billion yuan, and the total revenue of multinational pharmaceutical companies is 33.
64 billion yuan
.
However, compared with foreign companies, the performance growth rate of domestic pharmaceutical companies still has a good performance
.
Affected by factors such as volume purchases , the revenue of many foreign companies has declined.
Among them, Pfizer's revenue in 2020 has dropped by 20.
6% compared with 2019, which is a significant drop
.
As time progresses, in the public hospital market, what will the variety and ranking of domestic and foreign pharmaceutical companies look like? We will wait and see
.
hospital market.
The top 20 drugs
are affected by the new crown epidemic according to the data information of the medical geographic drug comprehensive database (PDB) for the whole year of 2020.
In 2020, the market sales of sample hospitals in China's key cities were 221.
31 billion yuan, a drop of 13% compared with the sales in 2019
.
In the past year, due to the impact of the new crown epidemic, the number of outpatient visits in hospitals has dropped sharply.
Neurological, anti-infection, cardiovascular, digestive system, miscellaneous, immunosuppressive drugs, endocrine and metabolic regulation drugs, blood and hematopoietic system drugs, and anti-tumor drugs The sales of medicines in the therapeutic areas such as medicines all showed negative growth
.
In terms of breakdown, the drug categories with the largest decline are neurologic medications, anti-infective medications, and cardiovascular medications, all with a decline of more than 20%; the smallest decline is anti-tumor drugs, which is about 4%.
At the same time, With a market share of 30.
3 billion yuan, oncology drugs accounted for the largest market share compared to drugs used in other diseases
.
In China's overall sample market, there are only 83 drugs with sales of more than 500 million in 2020, and this figure is still 111 in 2019
.
Specifically, in 2020, the top 20 drugs in sample hospitals’ sales include: human albumin, sodium chloride injection, dezocine injection, pegylated recombinant human granulocyte stimulating factor injection, and beauty for injection Ropenem, bevacizumab injection, cefoperazone sodium and sulbactam sodium for injection, osimertinib mesylate tablets, trastuzumab for injection, iodixanol injection, intravenous human immunoglobulin (pH4 ), tacrolimus capsules, rituximab injection, recombinant human thrombopoietin injection, pemetrexed disodium for injection, piperacillin sodium and tazobactam sodium for injection, docetaxel injection Solution, paclitaxel for injection (albumin-bound type), oxaliplatin for injection, butylphthalide sodium chloride injection
.
8Large variety, sales increase.
Among the top 20 drugs, there are 8 drugs.
Compared with 2019, sales have achieved further growth.
They are: human albumin, pegylated recombinant human granulocyte stimulation Factor injection, bevacizumab injection, osimertinib mesylate tablets, iodixanol injection, tacrolimus capsules, recombinant human thrombopoietin injection, butylphthalide sodium chloride injection
.
Among them, the largest increase was osimertinib mesylate tablets.
Its sales in sample hospitals rose from 1 billion yuan in 2019 to 1.
54 billion yuan in 2020, an increase of 54.
2%
.
It can be said that this growth rate is exceptionally impressive compared to the 10% growth rate of other drugs that are showing positive growth
.
Osimertinib mesylate is AstraZeneca's third-generation lung cancer targeted drug, with global sales of US$3.
2 billion in 2019
.
The product was approved to enter the Chinese market in March 2017 and contributed more than 500 million yuan in revenue within 9 months
.
It is the first domestic tumor drug approved for locally advanced or metastatic non-small cell lung cancer with positive EGFR T790M mutation
.
In October 2018, osimertinib mesylate (Teresa) was included in medical insurance through special negotiations on anticancer drugs.
The negotiation determined that the medical insurance payment standard was 510 yuan per tablet (80mg), an apparent decrease of 27%
.
After entering the medical insurance catalogue, osimertinib quickly increased its volume.
In the fourth quarter of 2018, its sales exceeded 300 million yuan, and its annual sales in 2019 exceeded 2.
3 billion yuan
.
Subsequently, osimertinib successfully renewed its contract and entered the 2019 edition of the National Medical Insurance Negotiation Catalog.
The latest data shows that in 2020, osimertinib will further enjoy the mass effect of entering medical insurance in the hospital market
.
It is worth noting that in September 2019, osimertinib was approved for the second indication for local late or metastasis with epidermal growth factor receptor exon 19 deletion or exon 21 (L858R) substitution mutation First-line treatment for adult patients with sexual non-small cell lung cancer
.
With the approval of new indications, osimertinib will continue to release greater sales potential
.
12 varieties, fell
in the remaining sales fell 12 kinds of medicines, the largest decline in paclitaxel for injection (albumin-bound), a decline of up to 25%, ranking regress from 13 in 2019 to 2020 The 18th place
.
Paclitaxel for injection (albumin-binding type) is an anti-microtubule drug used to treat metastatic breast cancer that has failed combined chemotherapy or breast cancer that recurs within 6 months after adjuvant chemotherapy
.
According to data from Meinenet, in 2019, the terminal paclitaxel sales of public medical institutions in China exceeded 7.
5 billion yuan, and paclitaxel for injection (albumin-bound type) accounted for 38.
6% of the market share
.
Paclitaxel injection (albumin-bound) as the top-ranking sales of cancer drug because of production enterprises full three national organizations be included in the second batch of drugs Jicai, eventually the new base, stone medicine, Henry won the bid, which bid CSPC The lowest price-747 yuan / branch
.
In March 2019, Xinji’s paclitaxel for injection (albumin-binding type) was suspended by the State Food and Drug Administration because its production facilities did not meet the requirements of China’s GMP, and the Joint Procurement Office subsequently announced its cancellation of the eligibility for the selection.
The market selected by Xinji Central Procurement Partitioned by CSPC and Hengrui Pharmaceuticals
.
In the second round of national centralized procurement, the procurement cycle of paclitaxel for injection (albumin-bound type) was two years.
With the sharp price cuts in centralized procurement, the reduction in sales in the hospital market is also expected
.
There may also be pemetrexed disodium for injection, which is similar to paclitaxel albumin, which has also been included in the collection
.
Sample hospitals, the top 10 pharmaceutical companies
According to the latest data in 2020, the top 10 pharmaceutical companies in the sample hospitals’ sales are: AstraZeneca, Pfizer, Jiangsu Hengrui, Roche, Yangzijiang Pharmaceutical, Novartis, CSPC, Bayer, Qilu Pharmaceutical, Chia Tai Tianqing Pharmaceutical Group
.
Among the top 10 pharmaceutical companies, only two have maintained positive growth.
They are CSPC and Qilu Pharmaceutical-Qilu Pharmaceutical's revenue in 2020 reached 4.
69 billion yuan, compared with 4.
27 billion yuan in 2019.
Increased revenue, an increase of 9.
8%
.
The top three pharmaceutical companies, AstraZeneca, Pfizer, and Jiangsu Hengrui, have revenues of 8.
86 billion yuan, 7.
72 billion yuan, and 6.
9 billion yuan, respectively, and their leading advantages are obvious
.
In general, among the top 10 pharmaceutical companies, domestic pharmaceutical companies and multinational pharmaceutical companies each occupy five seats, and the overall ranking of multinational pharmaceutical companies is high
.
From the perspective of total revenue, the total revenue of domestic pharmaceutical companies is 26.
34 billion yuan, and the total revenue of multinational pharmaceutical companies is 33.
64 billion yuan
.
However, compared with foreign companies, the performance growth rate of domestic pharmaceutical companies still has a good performance
.
Affected by factors such as volume purchases , the revenue of many foreign companies has declined.
Among them, Pfizer's revenue in 2020 has dropped by 20.
6% compared with 2019, which is a significant drop
.
As time progresses, in the public hospital market, what will the variety and ranking of domestic and foreign pharmaceutical companies look like? We will wait and see
.
